Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.6160
Nov 04 • 3:59 PM ET Dollar change+0.0052 Percentage change(0.85%)
Aftermarket Close
0.6105
Aftermarket • 5:54 PM ET Dollar change-0.0055 Percentage change(-0.89%)
Nov 03, 7:35 AMStandard BioTools completes sale of Microfluidics Business to ARCHIMED, which will operate divested unit as standalone company Biomark Scientific
Index
-
Market Cap
243.19M
Enterprise Value
-191.09M
Income
-69.20M
Sales
84.43M
Book/sh
1.41
Cash/sh
1.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
389
IPO
Feb 10, 2011
P/E
-
Forward P/E
-
PEG
-
P/S
2.88
P/B
0.44
P/C
0.53
P/FCF
-
EV/EBITDA
-
EV/Sales
-2.26
Quick Ratio
9.40
Current Ratio
9.75
Debt/Eq
0.05
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-0.18
EPS next Y
-0.16
EPS next Q
-0.02
EPS this Y
33.33%
EPS next Y
-60.00%
EPS next 5Y
-
EPS past 3/5Y
56.76% 23.22%
Sales past 3/5Y
-4.49% -9.19%
EPS Y/Y TTM
47.75%
Sales Y/Y TTM
-34.46%
EPS Q/Q
53.75%
Sales Q/Q
-0.85%
Insider Own
4.08%
Insider Trans
0.00%
Inst Own
74.79%
Inst Trans
-3.28%
ROA
-6.34%
ROE
-7.79%
ROIC
-12.00%
Gross Margin
50.82%
Oper. Margin
-55.98%
Profit Margin
-81.96%
SMA20
-2.74%
SMA50
-9.10%
SMA200
-31.67%
Trades
Shs Outstand
394.67M
Shs Float
378.61M
52W High
1.72 -64.19%
52W Low
0.59 4.74%
Volatility
4.11% 5.83%
ATR (14)
0.04
RSI (14)
40.30
Beta
1.50
Rel Volume
0.83
Avg Volume
1.22M
Volume
1,015,392
Perf Week
-0.16%
Perf Month
-14.68%
Perf Quarter
-23.01%
Perf Half Y
-36.40%
Perf YTD
-51.87%
Perf Year
-48.24%
Perf 3Y
-70.53%
Perf 5Y
-87.75%
Perf 10Y
-86.03%
Prev Close
0.61
Price
0.62
Change %
0.85%
Consensus
Hold
Avg. Price Target
$1.35
Implied Upside
+119.2%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 13, 2025Downgrade
TD logoTTD Cowen
Buy → Hold$1.55+151.6%
Feb 27, 2025Downgrade
KEY logoKKeyBanc Capital Markets
Overweight → Sector Weight
Apr 16, 2024Initiated
TD logoTTD Cowen
Buy$3.50+468.2%
Apr 04, 2024Initiated
JEF logoJJefferies
Buy$3.25+427.6%
Jul 12, 2023Initiated
KEY logoKKeyBanc Capital Markets
Overweight$4+549.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Egholm MichaelPresident & CEOApr 06 '26Option Exercise0.00196,51306,790,596Apr 08 09:55 PM
Kim Hanjoon AlexChief Financial OfficerApr 06 '26Option Exercise0.0070,18302,800,702Apr 08 09:55 PM
Casdin Partners Master Fund, LDirectorDec 04 '25Buy1.45150,000217,02072,100,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorDec 02 '25Buy1.42125,000177,51271,875,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorDec 03 '25Buy1.4475,000108,03771,950,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorNov 25 '25Buy1.307,550,0009,838,40571,750,000Nov 26 04:58 PM
Casdin Partners Master Fund, LDirectorNov 24 '25Buy1.43150,000214,87564,200,000Nov 26 04:58 PM
Casdin Partners Master Fund, LDirectorNov 20 '25Buy1.30450,000586,26064,050,000Nov 20 07:45 PM
Casdin Partners Master Fund, LDirectorNov 19 '25Buy1.28350,000448,91063,600,000Nov 20 07:45 PM
Casdin Partners Master Fund, LDirectorNov 18 '25Buy1.23275,000339,40563,250,000Nov 20 07:45 PM
Casdin Partners Master Fund, LDirectorNov 13 '25Buy1.20450,000541,39562,500,000Nov 17 06:58 PM
Casdin Partners Master Fund, LDirectorNov 14 '25Buy1.24250,000309,80062,750,000Nov 17 06:58 PM
Casdin Partners Master Fund, LDirectorNov 17 '25Buy1.22225,000275,58062,975,000Nov 17 06:58 PM
Casdin Partners Master Fund, LDirectorNov 12 '25Buy1.19375,000445,83862,050,000Nov 12 07:46 PM
Casdin Partners Master Fund, LDirectorNov 11 '25Buy1.20300,000358,80061,675,000Nov 12 07:46 PM
Casdin Partners Master Fund, LDirectorNov 10 '25Buy1.17275,000321,91561,375,000Nov 12 07:46 PM
Casdin Partners Master Fund, LDirectorNov 07 '25Buy1.12225,000252,76561,100,000Nov 12 07:46 PM
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.
PresidentDr. Michael Egholm Ph.D.
Chief Financial OfficerMr. Hanjoon Kim
Senior VP & Chief Business OfficerMr. Sean Mackay
VP & Chief Accounting OfficerMr. Jonathan Mickelsen
Vice President of Investor RelationsJohn Graziano